|
|
|
| Effect of 131I second treatment on serum related indexes and hypothyroidism rates in the treatment of Graves disease |
| CHEN Zhengping1 YI Jixiu2 LING Bing2 ZHAO Li2 PU Yinyan2 |
1.Department of Pharmacy, Chongqing Qianjiang Central Hospital, Chongqing 409000, China;
2.Department of Endocrine, Chongqing Qianjiang Central Hospital, Chongqing 409000, China |
|
|
|
Abstract Objective To investigate the effect of 131I second treatment on serum related indexes and hypothyroidism rates in the treatment of Graves disease. Methods From April 2015 to May 2017, 90 patients with Graves disease treated in Chongqing Qianjiang Central Hospital were selected, according to the random number table method, they were divided into control group (n=45) and study group (n=45). The patients in the control group were treated with Methamazole, while the patients in the research group were treated with 131I. The patients of two groups were treated for 12 months. The serum thyroid stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating an body (TSAb), thyroid stimulation-blocking antibody (TSBAb) and thyrotrophin receptor antibody (TRAb) of the two groups before and after treatment was compared. The hypothyroidism rates of the two groups after treatment was compared. Results There was no significant difference of the serum levels of TSH, FT3, FT4, TSAb, TSBAb and TRAb in the two groups before treatment (P > 0.05). After treatment, the serum TSH of the two groups was significantly higher than before treatment, the serum levels of FT3, FT4, TSAb, TSBAb and TRAb of the two groups were significantly lower than before treatment (P < 0.05); and the levels of serum TSH was higher than the control group after treatment, the levels of serum FT3, FT4, TSAb, TSBAb and TRAb in the study group were lower than the control group after treatment (P < 0.05). There was no significant difference in the incidence of hypothyroidism between the two groups after treatment (P > 0.05). Conclusion 131I in the second treatment of Graves disease can improve the serum levels of TSH, FT3, FT4, TSAb, TSBAb and TRAb, and the hypothyroidism rate between the 131I and Methamazole has no difference.
|
|
|
|
|
|
[1] 黄际远，宋文忠，戴庆靖，等.中老年Graves甲亢的临床特点及131碘的治疗效果[J].中国老年学杂志，2013，33（23）：5832-5834.
[2] 冯珏.Graves甲状腺功能亢进症的正确诊断与规范化治疗[J].临床荟萃，2016，31（3）：233-236.
[3] 庞敏红，卢志红.131碘联合复方甲亢片治疗毒性弥漫性甲状腺肿的临床研究[J].海南医学院学报，2016，22（12）：1270-1272.
[4] 胡德胜，石磊.131I治疗Graves甲亢临床疗效分析[J].标记免疫分析与临床，2015，22（3）：171-174.
[5] 吴晨辰，张晓梅.放射性131I在Graves病治疗中的应用进展[J].蚌埠医学院学报，2014，39（5）：697-700.
[6] 中华医学会核医学分会.131I治疗格雷夫斯甲亢指南（2013版）[J].中华核医学与分子影像杂志，2013，33（2）：83-94.
[7] 龚敏，周里钢.甲状腺功能减退症的诊断与治疗[J].上海医药，2015，36（7）：12-15，22.
[8] 朱琳，杨金，庄建安.硒联合小剂量131I治疗Graves甲亢的临床疗效观察[J].医学动物防制，2017，33（6）：700-702.
[9] 雷亚莉，鲍婷，王婷，等.成都地区居民甲状腺功能状况调查[J].川北医学院学报，2017，32（2）：276-279.
[10] 刘敏.巢湖地区131I和ATD治疗Graves甲亢的疗效分析[J].皖南医学院学报，2015，34（4）：347-349.
[11] 菅丽萍.131Ⅰ治疗巨大与非巨大甲状腺肿性Graves甲亢疗效对比[J].中国地方病防治杂志，2016，31（6）：709-710.
[12] 裴蕾蕾. Graves病患者抗甲状腺药物治疗复发相关因素分析[D].长春：吉林大学，2015.
[13] 曾白梅，袁灵，林世德.甲巯咪唑致肝损害的研究进展[J].海南医学，2018，29（24）：3530-3533.
[14] 赵丹青，左志华，张冲，等.甲巯咪唑治疗Graves病甲状腺功能亢进症致肌酸激酶增高2例报告[J].江苏大学学报：医学版，2017，27（3）：274-276.
[15] Bringmann IM，Van Leeuwen BL，Hennemann G，et al.Outcome of treatment of hyperthyroidism [J]. J Endoerinol Invest，1999，22（4）：250-256.
[16] 荚静芳，窦家庆.131碘在难治性甲亢合并白细胞减少症中的影响研究[J].中国预防医学杂志，2016，17（11）：880-881.
[17] 张王峰，马友凤，周梅，等.甲亢131碘治疗后早发甲减患者临床转归的分析[J].广西医科大学学报，2016，33（2）：320-322.
[18] 易吉秀，凌冰，吴平，等.131I和甲巯咪唑二次治疗复发型甲亢对患者骨密度及生化指标的影响[J].重庆医学，2018，47（31）：4070-4071，4074.
[19] 丁慧登，沃兴德，卢德赵.六味地黄汤对甲亢型肾阴虚大鼠肝线粒体蛋白质组的影响[J].国际中医中药杂志，2010，32（2）：105-107.
[19] 李瑞珍，潘香颖.不同剂量131I治疗甲状腺功能亢进症的效果比较[J].中外医学研究，2017，15（4）：25-27.
[20] 黄际远，宋文忠，戴庆靖，等.中老年Graves甲亢的临床特点及131碘的治疗效果[J].中国老年学杂志，2013， 33（23）：5832-5834. |
|
|
|
